AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25748452 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Electrical Stimulation (EECS) during rehabilitation
Number of subjects: 164
Study 25748452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EECS)
Number of subjects: 164
Study 25748452 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group (EECS)
Number of subjects: 164
Study 25748452 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational patients with movement thresholds during stimulation testing
Number of subjects: 164
Study 24559619 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (2.5 mg every 3 days for 6 months)
Number of subjects: 28
Study 24559619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22159301 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary counseling (home visits during the first year of life)
Number of subjects: 100
Study 22159301 — intervention group
Group type: COMPARATOR
Intervention: Control group (data collection visits at 6 and 12 months)
Number of subjects: 100
Study 20529205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg once daily
Number of subjects: 300
Study 20529205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg once daily
Number of subjects: 300
Study 20529205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg and 4 mg once daily
Number of subjects: 300
Study 20529205 — intervention group
Group type: COMPARATOR
Intervention: Prucalopride (1-4 mg once daily)
Number of subjects: 300
Study 18849320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg once daily on days 1‐21) plus capecitabine (1,000 mg/m2 every 12 hours on days 1‐14) every 21 days
Number of subjects: 399
Study 18849320 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (1,250 mg/m2 every 12 hours on days 1‐14) every 21 days
Number of subjects: 399
Study 18849320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 399
Study 18849320 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 399
Study 15640411 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 with small added amounts of ioxaglate (200 mgI/mL)
Number of subjects: 123
Study 15640411 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate alone
Number of subjects: 123
Study 15640411 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 with small added amounts of ioxaglate
Number of subjects: 123
Study 15640411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 14686228 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral ganciclovir therapy
Number of subjects: 0
Study 14686228 — intervention group
Group type: COMPARATOR
Intervention: CMV disease
Number of subjects: 0
Study 10555883 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 1 mg/kg
Number of subjects: 36
Study 10555883 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP571 10 mg/kg
Number of subjects: 36
Study 10555883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8532768 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mM putrescine in a eutectic vehicle (Fibrostat) for 1 month
Number of subjects: 43
Study 8532768 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 1 month
Number of subjects: 43
Study 1885075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA 1 g enema
Number of subjects: 113
Study 1885075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA 2 g enema
Number of subjects: 113
Study 1885075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA 4 g enema
Number of subjects: 113
Study 1885075 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 113
Study 31621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (24-week treatment)
Number of subjects: 123
Study 31621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (48-week treatment)
Number of subjects: 123
Study 31621933 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24-week treatment followed by edaravone)
Number of subjects: 123
Study 31621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (actual treatment)
Number of subjects: 123
Study 30243949 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-oriented integrative medicine approach combining dietary intervention and mind-body therapies followed by 8 weeks of telephonic health coaching
Number of subjects: 52
Study 30243949 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-oriented integrative medicine approach
Number of subjects: 52
Study 30243949 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 27777436 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Number of subjects: 900
Study 27777436 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac suppository alone
Number of subjects: 900
Study 25041058 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR (Mindfulness-Based Stress Reduction)
Number of subjects: 19
Study 22311867 — intervention group
Group type: EXPERIMENTAL
Intervention: Any TIMI rated bleed
Number of subjects: 744
Study 22311867 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-site access-related bleeds
Number of subjects: 744
Study 22311867 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-access bleeds
Number of subjects: 744
Study 20050717 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 80
Study 20050717 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 80
Study 18609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise (MI) for 2 weeks
Number of subjects: 48
Study 18609189 — intervention group
Group type: COMPARATOR
Intervention: High Intensity Exercise (HI) for 2 weeks
Number of subjects: 48
Study 16024585 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 4 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM4+NO)
Number of subjects: 42
Study 16024585 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 16 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM16+NO)
Number of subjects: 42
Study 16024585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12088576 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Number of subjects: 200
Study 12088576 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Number of subjects: 200
Study 9831776 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment analysis using DMFS increments
Number of subjects: 1754
Study 9831776 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence density (ID) analysis
Number of subjects: 1754
Study 9831776 — intervention group
Group type: COMPARATOR
Intervention: Subjects lost to follow-up
Number of subjects: 1754
Study 9831776 — intervention group
Group type: COMPARATOR
Intervention: Loss to follow-up
Number of subjects: 1754
Study 8523192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tyrosine supplementation (100 mg/kg body weight per day)
Number of subjects: 24
Study 8523192 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 24
Study 1950390 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution and rehydration with albumin 20% and crystalloids
Number of subjects: 300
Study 1950390 — intervention group
Group type: EXPERIMENTAL
Intervention: General intensive care treatment and monitoring with a pulmonary artery catheter
Number of subjects: 300
Study 7134227 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza aluminium oxide adsorbate vaccine
Number of subjects: 189
Study 7134227 — intervention group
Group type: COMPARATOR
Intervention: Aqueous vaccine
Number of subjects: 189
Study 7134227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 189
Study 31696544 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR1900 (20 mg)
Number of subjects: 6
Study 31696544 — intervention group
Group type: COMPARATOR
Intervention: Oral Sporanox (200 mg)
Number of subjects: 6
Study 31696544 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR1900 (10-35 mg)
Number of subjects: 6
Study 31668569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 81
Study 31668569 — intervention group
Group type: COMPARATOR
Intervention: Non-MSC treatment (prednisone and azithromycin)
Number of subjects: 81
Study 31668569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MSCs and non-MSCs)
Number of subjects: 81
Study 29929873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0
Study 29929873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26307163 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Piranha
Number of subjects: 74
Study 26307163 — intervention group
Group type: COMPARATOR
Intervention: Lumenis VersaCut
Number of subjects: 74
Study 24814090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 100 mg (subcutaneous at weeks 0, 4, and 8, with placebo at week 2)
Number of subjects: 124
Study 24814090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 300 mg plus loading dose (420 mg at week 0, followed by 300 mg at weeks 2, 4, and 8)
Number of subjects: 124
Study 24814090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 24814090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 100 mg
Number of subjects: 124
Study 24814090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 300 mg plus loading dose
Number of subjects: 124
Study 22266332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22266332 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel and placebo
Number of subjects: 21
Study 22266332 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel and an aromatase inhibitor
Number of subjects: 21
Study 19468278 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (2 mg/kg/h)
Number of subjects: 48
Study 19468278 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 48
Study 17346020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation and Prontosan gel
Number of subjects: 10
Study 17346020 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (implied control)
Number of subjects: 10
Study 14640988 — intervention group
Group type: EXPERIMENTAL
Intervention: +ATD
Number of subjects: 149
Study 14640988 — intervention group
Group type: COMPARATOR
Intervention: -ATD
Number of subjects: 149
Study 10960374 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide pad support width (Group 2)
Number of subjects: 40
Study 10960374 — intervention group
Group type: COMPARATOR
Intervention: Narrow pad support width (Group 1)
Number of subjects: 40
Study 8798100 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 40
Study 8798100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5 mg daily
Number of subjects: 40
Study 8798100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 40
Study 8798100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 0
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.2 mg
Number of subjects: 0
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 0
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 0
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine combined with Ephedrine
Number of subjects: 0
Study 1474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.08 mg, 0.1 mg, and 0.2 mg; Promethazine 12.5 mg and 25 mg
Number of subjects: 0
Study 1474161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 1 mL)
Number of subjects: 0
Study 6372084 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg suppositories
Number of subjects: 105
Study 6372084 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone 250 mg suppositories
Number of subjects: 105
Study 6372084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 31927346 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (12 supervised weekly sessions)
Number of subjects: 77
Study 31927346 — intervention group
Group type: COMPARATOR
Intervention: Written self-care advice (control)
Number of subjects: 77
Study 31870303 — intervention group
Group type: EXPERIMENTAL
Intervention: Target SNP-seq genotyping method using a panel of 92 perfect SNPs
Number of subjects: 271
Study 31870303 — intervention group
Group type: EXPERIMENTAL
Intervention: KASPar markers (35 core SNPs)
Number of subjects: 271
Study 31870303 — intervention group
Group type: EXPERIMENTAL
Intervention: STRUCTURE clustering
Number of subjects: 271
Study 31870303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine loci on chromosomes 1, 2, 3, 4, 6, and 12
Number of subjects: 271
Study 27936818 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 610
Study 27936818 — intervention group
Group type: COMPARATOR
Intervention: Comparison control conditions
Number of subjects: 610
Study 26065866 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (MRV) with gadofosveset trisodium (0.03 mmol/kg)
Number of subjects: 10
Study 26065866 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct thrombus imaging (DTHI) without contrast agent
Number of subjects: 10
Study 26065866 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MRV and DTHI
Number of subjects: 10
Study 23301632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117
Study 23301632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117
Study 23301632 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality and other malignancies
Number of subjects: 3117
Study 21658561 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + BMMNC
Number of subjects: 60
Study 21658561 — intervention group
Group type: COMPARATOR
Intervention: CABG only (placebo-control)
Number of subjects: 60
Study 19503764 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcarnosine (1% NAC) eye drops administered topically for 9 months
Number of subjects: 75
Study 19503764 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops administered topically for 9 months
Number of subjects: 75
Study 16995328 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea tincture (4 ml)
Number of subjects: 10
Study 16995328 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea tablets (12 tablets)
Number of subjects: 10
Study 16995328 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (both preparations)
Number of subjects: 10
Study 16995328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14972468 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) - 20-Hz square waves at a 300-microsecond pulse duration for 15 minutes twice daily for 1 month.
Number of subjects: 36
Study 14972468 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Magnetic Innervation (ExMI) - Neocontrol system, 20 minutes twice a week for 2 months, with pulse frequencies of 10 Hz and 50 Hz.
Number of subjects: 36
Study 14972468 — intervention group
Group type: COMPARATOR
Intervention: Control group - Pelvic floor muscle exercises only.
Number of subjects: 36
Study 11795386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388
Study 11795386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 9551748 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV (8.6+/‐3.6 cmH2O x L(‐1) and 3+/‐1.3 cmH2O x L(‐1)x s(‐1) of volume and flow assistance, EPAP: 1 cmH2O)
Number of subjects: 15
Study 9551748 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV (inspiratory pressure support: 12‐16 cmH2O; EPAP: 1 cmH2O)
Number of subjects: 15
Study 9551748 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (6 cmH2O)
Number of subjects: 15
Study 9551748 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation (CPAP: 1 cmH2O)
Number of subjects: 15
Study 8068939 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses of 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d
Number of subjects: 20
Study 8068939 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses starting from 2.5 micrograms/kg/d
Number of subjects: 20
Study 8068939 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses of 10 and 20 micrograms/kg/d
Number of subjects: 20
Study 8068939 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6)
Number of subjects: 20
Study 3174723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (80 mg/daily) for 5 days
Number of subjects: 20
Study 3174723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) for 5 days
Number of subjects: 20
Study 30314560 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) intervention including clinical coaching by a gerontology nurse specialist (GNS) and a review of selected high-risk residents' care-plans.
Number of subjects: 1296
Study 30314560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity model using a shorter, staggered time period for intervention effect testing.
Number of subjects: 1296
Study 27631544 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo (tracksuit jacket with integrated heating elements and dry land-based exercise routine)
Number of subjects: 25
Study 25439611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornea from a donor with diabetes
Number of subjects: 1090
Study 25439611 — intervention group
Group type: COMPARATOR
Intervention: Cornea from a donor without diabetes
Number of subjects: 1090
Study 24156389 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and magnesium (1g Ca Gluconate plus 1g MgSO4)
Number of subjects: 20
Study 24156389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 20
Study 21130349 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation (KT) interventions
Number of subjects: 0
Study 18323507 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tissue segmentation protocol with lesion segmentation
Number of subjects: 59
Study 16551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity index for patients with aortic sclerosis
Number of subjects: 48
Study 16551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity index for patients with mild to moderate AS
Number of subjects: 48
Study 16551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity index for patients with severe AS
Number of subjects: 48
Study 16551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic jet velocity by echocardiography
Number of subjects: 48
Study 16551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Square root of the maximum aortic valve gradient by cardiac catheterization
Number of subjects: 48
Study 14972007 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 45
Study 14972007 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 45
Study 10931080 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075 mg/day to 0.6 mg once daily)
Number of subjects: 39
Study 10931080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg/week to 1.5 mg twice weekly)
Number of subjects: 39
Study 9294797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous screws
Number of subjects: 0
Study 9294797 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (SHS) and derotation screw (DRS) composite
Number of subjects: 0
Study 8362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined curriculum
Number of subjects: 48
Study 8362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Curricula teaching refusal skills
Number of subjects: 48
Study 8362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Curricula correcting social misperceptions
Number of subjects: 48
Study 8362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Single programs
Number of subjects: 48
Study 2823841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU low molecular weight heparin (LMWH)
Number of subjects: 8
Study 2823841 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU low molecular weight heparin (LMWH)
Number of subjects: 8
Study 2823841 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU low molecular weight heparin (LMWH)
Number of subjects: 8
Study 2823841 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU unfractionated heparin
Number of subjects: 8
Study 30288474 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat 70 µg/kg/day
Number of subjects: 37
Study 30288474 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat 140 µg/kg/day
Number of subjects: 37
Study 30288474 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat 280 µg/kg/day
Number of subjects: 37
Study 30288474 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of maralixibat combined
Number of subjects: 37
Study 30288474 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat (any dose)
Number of subjects: 37
Study 30288474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 28355577 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training task
Number of subjects: 70
Study 28355577 — intervention group
Group type: COMPARATOR
Intervention: Placebo task
Number of subjects: 70
Study 23575004 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone wax
Number of subjects: 184